CYTO News & Events

Altamira Therapeutics announced that its associate company Altamira Medica has obtained marketing approval from the National Medical Products Administration of China for its Bentrio nasal spray in allergic rhinitis. The clearance will allow Nuance Pharma, Medica's licensee and distribution partner, to start marketing and distributing Bentrio in Mainland China.

Altamira Therapeutics announced that its nanoparticle-based delivery platform was tested also for circular mRNA. In vitro experiments demonstrated successful transfection of cells and significantly higher protein expression than with linear mRNA, based on which the Company has filed a provisional patent application with the United States Patent Office. Altamira will start offering its platform to biotech and pharma companies for use with circular RNA under the CycloPhore label, complementing its offerings for siRNA and mRNA.

Altamira Therapeutics announced that on December 18, 2024 it received notice that the Nasdaq Hearings Panel had determined to delist the Company's common shares from The Nasdaq Stock Market due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. The Company's common shares will be delisted from Nasdaq at the open of trading on December 20, 2024 and are expected to then begin trading on the OTCQB marketplace under the ticker symbol "CYTOF."

Altamira Therapeutics announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC that it no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the company's listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. The letter stated that the Company is not eligible for any cure period due to the fact that the Company effectuated one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The company intends to appeal this determination to a hearing panel. The hearing request will result in a stay of any suspension or delisting action pending the hearing. There can be no assurance that the Panel will grant the company's request for continued listing or that any extension will be granted by the Panel.